The role of biosimilars in value-based oncology care

Biopharmaceuticals (biologics) represent one of the fastest growing sectors of cancer treatment. They are recommended for treating underlying cancer and as supportive care for management of treatment side effects. Given the high costs of cancer care and the need to balance health care provision and...

Full description

Saved in:
Bibliographic Details
Published in:Cancer management and research 2018-01, Vol.10, p.4591-4602
Main Authors: Patel, Kashyap B, Arantes, Jr, Luiz H, Tang, Wing Yu, Fung, Selwyn
Format: Article
Language:English
Subjects:
Analysis
Anemia
Bevacizumab
Biological products
biologics
Biopharmaceuticals
biosimilars
Budgets
Cancer
Cancer therapies
Cancer treatment
Cetuximab
Chemotherapy
Cost control
Drugs
Epidermal growth factor
Epoetin alfa
Expenditures
FDA approval
Gene expression
Health care industry
Health care policy
Health care reform
Hematology
Impact analysis
Internet
Manufacturing
Medicaid
Medical care quality
Medicare
Neutropenia
Oncology
patient access
Patient care
Patients
Pegfilgrastim
Physicians
R&D
Research & development
Review
supportive care
value-based care
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Biopharmaceuticals (biologics) represent one of the fastest growing sectors of cancer treatment. They are recommended for treating underlying cancer and as supportive care for management of treatment side effects. Given the high costs of cancer care and the need to balance health care provision and associated budgets, patient access and value are the subject of discussion and debate in the USA and globally. As the costs of biologics are high, biosimilars offer the potential of greater choice and value, increased patient access to treatment, and the potential for improved outcomes. Value-based care aims to improve the quality of care, while containing costs. The Centers for Medicare & Medicaid Services (CMS) has developed value-based care programs as alternatives to fee-for-service reimbursement, including in oncology, that reward health care providers with incentive payments for improving the quality of care they provide. It is anticipated that CMS payments in oncology care will be increasingly tied to measured performance. This review provides an overview of value-based care models in oncology with a focus on CMS programs and discusses the contribution of biosimilars to CMS value-based care objectives. Biosimilars may provide an important tool for providers participating in value-based care initiatives, resulting in cost savings and efficiencies in the delivery of high-value care through expanded use of biologic treatment and supportive care agents during episodes of cancer care.
ISSN:1179-1322
1179-1322
DOI:10.2147/CMAR.S164201